Cancer cells can limit the efficacy of KRAS inhibitors through several mechanisms, such as activating other signaling pathways, developing new resistance mutations, or downregulating multiple immune signals associated with the activation of anti-cancer immune responses 15. This evidence concerns the gene KRAS and cancer.